SCHEMBL3731464

SCHEMBL3731464

CC1c2ccccc2N(Cc2nc3cc(CN)ccc3n2CCCC(F)(F)F)C(=O)N1C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2879875 0.88 F10 (0.38)
SCHEMBL2872607 0.87 BCHE (0.37)
SCHEMBL2882239 0.86 C5AR1 (0.36)
SCHEMBL2882240 0.86 C5AR1 (0.36)
SCHEMBL2882242 0.84 C5AR1 (0.36)
SCHEMBL3731277 0.83
SCHEMBL2866176 0.83
Methyl Alcohol SCHEMBL2866169 0.82
Acetonitrile SCHEMBL2873581 0.81 C5AR1 (0.41)
SCHEMBL2870188 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100278835-A1 NOVEL COMPOUNDS 660 ASTRAZENECA UK LIMITED (GB) 2010-11-04 US claimed
EP-3177299-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS Alios Biopharma, Inc. (US) 2017-06-14 EP disclosed
US-20160045528-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS ALIOS BIOPHARMA, INC. 2016-02-18 US disclosed
WO-2016022464-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS ALIOS BIOPHARMA, INC. (US) 2016-02-11 WO disclosed
US-20100278835-A1 NOVEL COMPOUNDS 660 ASTRAZENECA UK LIMITED (GB) 2010-11-04 US disclosed